Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENOV vs RBOT.WS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENOV Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

ENOV Overall Winner 6-Pillar Tally: ENOV 5 – 0 RBOT.WS (1 Tie) Matrix Metrics: ENOV 9 – 1 RBOT.WS

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENOV carries a Unified Composite Score of 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (4.0% vs. N/A operating margin) and revenue trajectory (+1.8% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENOV vs RBOT.WS
ENOV NYSE Head-to-Head Winner
Enovis Corporation
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$25.47
-2.9% 1D
Market Cap $1.5B
TTM Revenue $2.31B
Forward P/E 7.3x
Beta / 30D Vol 0.75β · 101% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 15.0 Fund 28.0 Flow 50.0 Mom 21.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.2% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $25.18 · SMA50: $21.30
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (ENOV 5 – 0 RBOT.WS)

Columns: Metric · ENOV · RBOT.WS
1. Valuation Multiples ENOV
Forward P/E 7.3x N/M
Trailing P/E 7.5x N/M
PEG Ratio 1.90x N/M
EV / Revenue 0.7x N/M
2. Growth & Scale ENOV
Revenue Growth (YoY) +1.8% N/A
Earnings Growth (YoY) +153.1% N/A
TTM Revenue (USD) $2.31B N/A
Market Cap $1.5B N/A
3. Profitability & Quality ENOV
Gross Margin 61.3% N/A
Operating Margin 4.0% N/A
Net Profit Margin -22.9% N/A
Return on Equity (ROE) -29.9% N/A
4. Balance Sheet & Cash Flow ENOV
Cash Generation (TTM) $387M EBITDA N/A
Cash Flow Margin 16.8% EBITDA Mgn N/A
Net Cash / Leverage $25.88 Book/Sh · -29.9% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 65.6% (43rd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ENOV
OpEx & R&D Intensity 57.3% of Rev ($1.32B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENOV (9) vs RBOT.WS (1)
Institutional Metric ENOV RBOT.WS Criterion Row Edge
Market Capitalization
Scale
$1.5B N/A Larger Scale ENOV
Trailing P/E Ratio
Valuation
7.5x N/M Lower Multiple ENOV
Forward P/E Ratio
Valuation
7.3x N/M Lower Multiple ENOV
Revenue Growth (YoY)
Growth
+1.8% N/A Higher Growth ENOV
Operating Margin (TTM)
Profitability
4.0% N/A Higher Margin ENOV
Net Profit Margin
Profitability
-22.9% N/A Higher Margin ENOV
Return on Equity (ROE)
Capital Efficiency
-29.9% N/A Higher ROE ENOV
52-Week Range Position
Momentum
59% ($17–$32) 0% ($0–$0) Stronger Trend ENOV
Beta / 30D Volatility
Risk Regime
0.75β · 101% Vol N/A Lower Realized Risk ENOV
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 50.1 / 100 (HOLD) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
$2.31B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.90x PEG · 0.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$387M EBITDA ($25.88 Book/Sh · -29.9% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENOV +65.93 pp
ENOV: -1.27% · RBOT.WS: -67.2%
3M Horizon ENOV +65.93 pp
ENOV: -1.27% · RBOT.WS: -67.2%
6M Horizon ENOV +65.93 pp
ENOV: -1.27% · RBOT.WS: -67.2%
1Y Horizon ENOV +65.93 pp
ENOV: -1.27% · RBOT.WS: -67.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENOV vs RBOT.WS. Trailing 12-month operating profitability (ENOV 4.0% vs RBOT.WS N/A) and valuation multiples (ENOV 7.3x vs RBOT.WS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ENOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.31B
Gross Margin61.3%
Op. Margin4.0%
ROE / Fwd P/E-29.9% · 7.3x
RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.6%
IV Percentile 43rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENOV Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.5B market capitalization and 4.0% operating margin.
OpEx & R&D Reinvestment 57.3% of Rev ($1.32B)
90D Engineering Disclosures 0 Published
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENOV vs RBOT.WS Key Questions & Quantitative Answers

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENOV carries a Unified Composite Score of 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (4.0% vs. N/A operating margin) and revenue trajectory (+1.8% vs. N/A YoY).

ENOV leads the Growth & Scale pillar: ENOV posts +1.8% YoY revenue growth and +153.1% YoY earnings growth on $2.31B TTM revenue (61.3% gross margin, 4.0% operating margin), compared with RBOT.WS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ENOV generates $2.31B in USD-normalized revenue versus N/A for RBOT.WS. In operating R&D and SG&A reinvestment, ENOV deploys 57.3% of Rev ($1.32B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RBOT.WS.

ENOV screens cheaper on headline valuation multiples. ENOV trades at 7.3x Forward P/E, 7.5x Trailing P/E, 1.90x PEG, and 0.7x EV/Revenue (16.8% EBITDA margin), whereas RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENOV (-29.9% ROE) versus RBOT.WS (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ENOV carries 65.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.75β · 101% Vol realized risk). By comparison, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.